|
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
RECRUITINGSponsored by BillionToOne Inc.
Actively Recruiting
SponsorBillionToOne Inc.
Started2026-01-10
Est. completion2027-12
Eligibility
SexFEMALE
Healthy vol.Accepted
Locations6 sites
View on ClinicalTrials.gov →
NCT07643896
Summary
The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.
Eligibility
Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria: * pregnant individuals between 10 and 20 weeks of gestation * singleton gestation Exclusion Criteria: \- active cancer
Conditions8
22q11.2 Deletion SyndromeAneuploidyDown Syndrome (Trisomy 21)Heart DiseasePregnant IndividualsSex Chromosome AbnormalitiesTrisomy 13Trisomy 18
Locations6 sites
Valley Perinatal Services
San Gabriel Valley Perinatal Medical Group
Sarasota Memorial Health Care System
Pediatrix Medical Group of Georgia
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorBillionToOne Inc.
Started2026-01-10
Est. completion2027-12
Eligibility
SexFEMALE
Healthy vol.Accepted
Locations6 sites
View on ClinicalTrials.gov →
NCT07643896